Neurogene
NGNE----
Neurogene (NGNE)
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Neurogene Analyst Rating
View MoreForecast & Rating
Jul 9, 2026Price forecast
$81.71134.14%
Forecast & RatingStrong buy
9analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 11 at 09:35 AM
Neurogene (NGNE) Receives a Buy from LifeSci Capital
- PUBT · Jul 7 at 08:09 PM
Neurogene President, CFO Christine Mikail Cvijic sells 4,800 shares for $173,468.40
- Tip Ranks · Jul 7 at 10:45 AM
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
- PUBT · Jul 6 at 03:01 PM
Neurogene grants inducement stock options for 96,450 shares to new employees
- StockTitan · Jul 6 at 07:01 AM
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NGNE Stock News
- PUBT · Jul 2 at 05:43 PM
Neurogene President, CFO Christine Mikail Cvijic sells 4,800 common shares for $166,407.28
